دورية أكاديمية
أعرض في EDS

SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort.

التفاصيل البيبلوغرافية
العنوان: SLCO1B1*5 is protective against non-senile cataracts in cohort prescribed statins: analysis in a British-South Asian cohort.
المؤلفون: Magavern EF; William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK., van Heel DA; Blizard Institute, Queen Mary University of London, London, E1 2AB, UK., Smedley D; William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK., Caulfield MJ; William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK. m.j.caulfield@qmul.ac.uk.
مؤلفون مشاركون: Genes & Health Research Team
المصدر: The pharmacogenomics journal [Pharmacogenomics J] 2023 Sep; Vol. 23 (5), pp. 134-139. Date of Electronic Publication: 2023 May 23.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101083949 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-1150 (Electronic) Linking ISSN: 1470269X NLM ISO Abbreviation: Pharmacogenomics J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Avenet, NJ : Nature Pub. Group, c2001-
مواضيع طبية MeSH: Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects , Cataract*/chemically induced , Cataract*/epidemiology , Cataract*/genetics, Humans ; Male ; Adult ; Female ; Genotype ; Liver-Specific Organic Anion Transporter 1/genetics
مستخلص: Background: Reported association between statin use and cataract risk is controversial. The SLCO1B1 gene encodes a transport protein responsible for statin clearance. The aim of this study was to investigate a possible association between the SLCO1B1*5 reduced function variant and cataract risk in statin users of South Asian ethnicity.
Methods: The Genes & Health cohort consists of British-Bangladeshi and British-Pakistani participants from East London, Manchester and Bradford, UK. SLCO1B1*5 genotype was assessed with the Illumina GSAMD-24v3-0-EA chip. Medication data from primary care health record linkage was used to compare those who had regularly used statins compared to those who had not. Multivariable logistic regression was used to test for association between statin use and cataracts, adjusting for population characteristics and potential confounders in 36,513 participants. Multivariable logistic regression was used to test association between SLCO1B1*5 heterozygotes or homozygotes and cataracts, in subgroups having been regularly prescribed statins versus not.
Results: Statins were prescribed to 35% (12,704) of participants (average age 41 years old, 45% male). Non-senile cataract was diagnosed in 5% (1686) of participants. An apparent association between statins and non-senile cataract (12% in statin users and 0.8% in non-statin users) was negated by inclusion of confounders. In those prescribed a statin, presence of the SLCO1B1*5 genotype was independently associated with a decreased risk of non-senile cataract (OR 0.7 (CI 0.5-0.9, p 0.007)).
Conclusions: Our findings suggest that there is no independent association between statin use and non-senile cataract risk after adjusting for confounders. Among statin users, the SLCO1B1*5 genotype is associated with a 30% risk reduction of non-senile cataracts. Stratification of on-drug cohorts by validated pharmacogenomic variants is a useful tool to support or repudiate adverse drug events in observational cohorts.
(© 2023. The Author(s).)
References: British National Formulary. BNF: drugs: atorvastatin. National Institute for Health and Care Excellence; 2022. https://bnf.nice.org.uk/drugs/atorvastatin/#indications-and-dose accessed October 3, 2022.
Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The ‘top 100’ drugs and classes in England: an updated ‘starter formulary’ for trainee prescribers. Br J Clin Pharmacol. 2018;84:2562–71. (PMID: 10.1111/bcp.13709299757996177714)
Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013. JAMA Cardiol. 2017;2:56. (PMID: 10.1001/jamacardio.2016.470027842171)
Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39:2526–39. (PMID: 10.1093/eurheartj/ehy182297182536047411)
Liu Y-C, Wilkins M, Kim T, Malyugin B, Mehta JS. Cataracts. Lancet. 2017;390:600–12. (PMID: 10.1016/S0140-6736(17)30544-528242111)
Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts. JAMA Ophthalmol. 2013;131:1427. (PMID: 10.1001/jamaophthalmol.2013.457524052188)
Wise SJ, Nathoo NA, Etminan M, Mikelberg FS, Mancini GBJ. Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and the United States. Can J Cardiol. 2014;30:1613–9. (PMID: 10.1016/j.cjca.2014.08.02025475465)
Kostis JB, Dobrzynski JM. Prevention of cataracts by statins. J Cardiovasc Pharmacol Ther. 2014;19:191–200. (PMID: 10.1177/107424841351169024311734)
Bang CN, Greve AM, la Cour M, Boman K, Gohlke-Bärwolf C, Ray S, et al. Effect of randomized lipid lowering with simvastatin and ezetimibe on cataract development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). Am J Cardiol. 2015;116:1840–4. (PMID: 10.1016/j.amjcard.2015.09.02626602073)
Yu S, Chu Y, Li G, Ren L, Zhang Q, Wu L. Statin use and the risk of cataracts: a systematic review and meta‐analysis. J Am Heart Assoc. 2017;6. https://doi.org/10.1161/JAHA.116.004180 .
Alves C, Mendes D, Batel Marques F. Statins and risk of cataracts: a systematic review and meta‐analysis of observational studies. Cardiovasc Ther. 2018;36:e12480. (PMID: 10.1111/1755-5922.1248030597753)
Ghouse J, Ahlberg G, Skov AG, Bundgaard H, Olesen MS. Association of common and rare genetic variation in the 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase gene and cataract risk. J Am Heart Assoc. 2022;11. https://doi.org/10.1161/JAHA.122.025361 .
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28. (PMID: 10.1056/NEJMoa04237815635109)
Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics. 2010;20:211–6. (PMID: 10.1097/FPC.0b013e328333b99c199528713086841)
SEARCH Collaborative Group; Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy — a genomewide study. N Engl J Med. 2008;359:789–99.
Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82:726–33. (PMID: 10.1038/sj.clpt.610022017473846)
Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016. Nucleic Acids Res. 2016;44:D710–D716. (PMID: 10.1093/nar/gkv115726687719)
Ensembl. Variant: rs4149056; population genetics. ensembl.org. 2022. https://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=12:21178115-21179115;v=rs4149056;vdb=variation;vf=730080021 . Accessed 3 Oct 2022.
George J, Mathur R, Shah AD, Pujades-Rodriguez M, Denaxas S, Smeeth L, et al. Ethnicity and the first diagnosis of a wide range of cardiovascular diseases: associations in a linked electronic health record cohort of 1 million patients. PLoS ONE. 2017;12:e0178945. (PMID: 10.1371/journal.pone.0178945285989875466321)
Finer S, Martin HC, Khan A, Hunt KA, MacLaughlin B, Ahmed Z, et al. Cohort profile: East London Genes & Health (ELGH), a community-based population genomics and health study in British Bangladeshi and British Pakistani people. Int J Epidemiol. 2020;49:20–21i. (PMID: 10.1093/ije/dyz17431504546)
Chen M-H, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell. 2020;182:1198–1213.e14. (PMID: 10.1016/j.cell.2020.06.045328884937480402)
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75. (PMID: 10.1086/519795177019011950838)
Purcell S, Chang C. PLINK 2.0. www.cog-genomics.org/plink/2.0/ .
RStudio Team. RStudio: integrated development environment for R. Boston, MA: PBC; 2022. https://www.r-project.org/ .
Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics. 2006;16:873–9. (PMID: 10.1097/01.fpc.0000230416.82349.9017108811)
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, et al. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2022;8:85–99. (PMID: 10.1093/ehjcvp/pvab01833638977)
Genes & Health. Genes & Health: GeneAndHealth_PHENOTYPES. 2022. https://docs.google.com/spreadsheets/d/1ipwdF2j_owfr_QbkDYk1rk0TW3KtdfQYVQn-Vf-o38s/edit#gid=1517436704 . Accessed 29 Sep 2022.
Biobank UK. UK Biobank first occurrence of health outcomes defined by 3-character ICD10 code. 2019. https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/first_occurrences_outcomes.pdf .
Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic stenosis (SEAS) Study. Am J Cardiol. 2007;99:970–3. (PMID: 10.1016/j.amjcard.2006.10.06417398194)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust; United Kingdom MRC_ Medical Research Council
المشرفين على المادة: 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
0 (SLCO1B1 protein, human)
0 (Liver-Specific Organic Anion Transporter 1)
تواريخ الأحداث: Date Created: 20230523 Date Completed: 20230920 Latest Revision: 20231015
رمز التحديث: 20231016
مُعرف محوري في PubMed: PMC10506906
DOI: 10.1038/s41397-023-00307-w
PMID: 37221222
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-1150
DOI:10.1038/s41397-023-00307-w